BioNTech SE
Nasdaq BNTX · Mainz, Germany
Works in Dermatology · Genetic & rare · GI & liver · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
BioNTech SE is a clinical trial sponsor based in Mainz, Germany, listed as Nasdaq BNTX. It has 30 active clinical trials with 12,847 planned participants, across 11 therapeutic areas. Since 2021 it has completed 36 trials and stopped 8 early.
Trial track record · since 2021
Financials · Nasdaq BNTX
Pipeline · 30 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about BioNTech SE
BioNTech SE is lead sponsor of 30 active clinical trials on ClinicalTrials.gov, with 12,847 planned participants, in Dermatology, Genetic & rare, GI & liver, Immunology and other areas. Since 2021 it has completed 36 trials and stopped 8 early.
BioNTech SE is based in Mainz, Germany and is listed as Nasdaq BNTX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with BioNTech SE; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with BioNTech SE. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.